Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
featured
Cladribine tablets: Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptiMAlly controlled patientS previously Taking oral disEase-modifying dRugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2)

setting and after suboptimal response to any oral DMD approved in the US for RMS Secondary Objectives: To assess PROs and treatment adherence during treatment with cladribine tablets

cladribine
  • 45 views
  • 24 Nov, 2020
  • 1 location
featured
CLadribine tablets: Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS)

setting and after suboptimal response to any injectable DMD approved in the US for RMS Secondary Objectives: To assess PROs and treatment adherence during treatment with cladribine

cladribine
  • 50 views
  • 24 Nov, 2020
  • 1 location
Spironolactone Versus Prednisolone in DMD

This is a randomized, open-label, pilot clinical trial of spironolactone suspension versus oral prednisolone for use in Duchenne muscular dystrophy. The goals are to determine the safety of 6

muscle biopsy
dmd gene
weakness
prednisolone
ejection fraction
  • 36 views
  • 23 Jan, 2021
  • 1 location
Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD

This study will collect MRI from healthy volunteer boys and boys with Duchenne Muscular Dystrophy (DMD) to help researchers identify and validate cardiac MRI biomarkers to better understand the

muscular dystrophy
genetic testing
  • 30 views
  • 23 Jan, 2021
  • 2 locations
Study of SRP-4045 and SRP-4053 in DMD Patients

The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion mutations

deletion mutation
duchenne muscular dystrophy
forced vital capacity
muscular dystrophy
corticosteroids
  • 0 views
  • 24 Mar, 2021
  • 78 locations
A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older

drug test
pneumococcal vaccine
total bilirubin
calcium
electrolytes
  • 60 views
  • 25 Jul, 2021
  • 30 locations
A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every two weeks in ambulatory subjects with Duchenne muscular

serum electrolyte
duchenne muscular dystrophy
prednisolone
corticosteroids
calcium
  • 0 views
  • 25 Jul, 2021
  • 49 locations
Heart Rate Variability Biofeedback Training in Psychogenic Disorders

To study whether Heart Rate Variability (HRV) biofeedback training can improve abnormal head posture and painful symptomatology in patients with "cervical dystonia" not selected for DBS after extensive screening in a specialized unit but diagnosed " dysfunctional ". Patients of the respiratory coherence group will receive HRV biofeedback training for …

  • 0 views
  • 13 May, 2021
  • 1 location
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.

muscular dystrophy
duchenne muscular dystrophy
  • 219 views
  • 09 Jul, 2021
  • 43 locations
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP

  • 0 views
  • 10 Jul, 2021
  • 7 locations